| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. ("EUDA Health"), has signed a Letter of Intent (the "LOI") to potentially acquire GO POSB Organoids Pte Ltd ("GO POSB"), a biotechnology company formed in Singapore.
GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical concerns linked to embryonic stem cells, making them one of the most promising frontiers in biotechnology.
Strategic Expansion into iPSC Solutions
Under the LOI, EUDA and GO POSB are exploring the establishment of a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China. The facility would serve as a hub to store, expand, and distribute iPSC solutions to hospitals, clinics, and research centers across China, subject to regulatory approvals. EUDA will provide funding for the build-out while the two companies collaborate with Singapore's Agency for Science, Technology and Research (A*STAR) to advance iPSC research, conduct clinical trials, and accelerate regulatory pathways for therapeutic applications.
The collaboration will position EUDA to supply B2B iPSC solutions to the downstream healthcare ecosystem, including hospitals, regenerative clinics, and biotech developers. Beyond core therapeutic applications, the platform also opens future opportunities for off-the-shelf iPSC-derived product lines tailored for Asia's wellness and aesthetics markets, such as iPSC-based hair rejuvenation and facial treatments. These initiatives are designed to directly complement EUDA's growing portfolio of stem cell treatments and supplements, reinforcing the Company's integrated approach to longevity and regenerative health.
Posted In: EUDA
